Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1494

Sort by

Sort Order Select

Journal Articles

Vacuolization of hematopoietic precursors: an enigma with multiple etiologies

Carmelo Gurnari, Simona Pagliuca, Lisa Durkin, Laila Terkawi, Hassan Awada, Sunisa Kongkiatkamon, Misam Zawit, Eric D. Hsi, Hetty E. Carraway, Heesun J. Rogers, Valeria Visconte, Jaroslaw P. Maciejewski

Blood (2021) 137 (26): 3685–3689.

https://doi.org/10.1182/blood.2021010811

Published: 2021

Includes: Supplemental data

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Bone marrow aspirate LE cells at acute lupus presentation

Ira J. Miller

Blood (2020) 135 (3): 230.

https://doi.org/10.1182/blood.2019003449

Published: 2020

Journal Articles

Acid-Based Decalcification Methods Compromise Genomic Profiling from DNA and RNA

Ian Duncan, Natalie Danziger, Daniel Duncan, MD, Amanda Hemmerich, MD, Claire Edgerly, MD, Richard Huang, MD, Jo-Anne Vergilio, MD, Julia A Elvin, MD PhD, Jie He, PhD, Nicholas Britt, Prasanth Reddy, MD, Pratheesh Sathyan, MD, Brian Alexander, MD, Jeffrey S. Ross, MD, Charlotte Brown, PhD, Shakti H. Ramkissoon, MD PhD, Eric A. Severson, MD, PhD, MMSc

Blood (2019) 134 (Supplement_1): 4659.

https://doi.org/10.1182/blood-2019-131362

Published: 2019

Journal Articles

Single Cell Transcriptomic Analysis of the Multiple Myeloma Bone Marrow Identifies a Unique Inflammatory Stromal Cell Population Associated with TNF Signaling

Madelon M.E. de Jong, MD, Zoltan Kellermayer, MD PhD, Natalie Papazian, M Duin, Annemiek Broyl, MD PhD, Pieter Sonneveld, Tom Cupedo

Blood (2019) 134 (Supplement_1): 690.

https://doi.org/10.1182/blood-2019-123012

Published: 2019

Journal Articles

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Chong Chyn Chua, MBBS, John Reynolds, PhD, Jessica M Salmon, PhD, Chun Fong, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Ing Soo Tiong, MBBS,FRACP,FRCPA, Shaun Fleming, MBBS,, Sarah MacRaild, Donia M Moujalled, PhD, Giovanna Pomilio, Nik Cummings, Julie McManus, Adam Ivey, BSc, MSc, PhD, Purvi M Kakadia, PhD, Stefan K. Bohlander, MD, Andrew W. Roberts, MBBS, PhD FRACP, FRCPA, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 462.

https://doi.org/10.1182/blood-2019-126640

Published: 2019

Journal Articles

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Blood (2019) 134 (Supplement_1): 692.

https://doi.org/10.1182/blood-2019-123143

Published: 2019

Journal Articles

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

Blood (2019) 134 (Supplement_1): 610.

https://doi.org/10.1182/blood-2019-125968

Published: 2019

Journal Articles

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Brenda J Chyla, PhD, Jason Harb, PhD, Christine Mantis, PhD, Jacob J Riehm, PhD, Jeremy A. Ross, PhD, Yan Sun, PhD, Xin Huang, PhD MD, Qi Jiang, PhD, Monique Dail, PhD, Franklin V. Peale, Jr., MD PhD, Jalaja Potluri, MD, John Hayslip

Blood (2019) 134 (Supplement_1): 546.

https://doi.org/10.1182/blood-2019-128373

Published: 2019

Journal Articles

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

Abhishek Maiti, MBBS, Caitlin R. Rausch, PharmD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Maro Ohanian, DO, Nicholas J. Short, MD, Yesid Alvarado, MD, Christopher B. Benton, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Musa Yilmaz, MD, Nitin Jain, MD, Steven M. Kornblau, MD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Alessandra Ferrajoli, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Lucia Masarova, MD, Michael E. Rytting, MD, Philip A. Thompson, MBBS, Sa A Wang, MD, Sergej Konoplev, Zhining Chen, Maitrayee Goswami, Rita Maduike, Julio A Guerrero, RN, Qi Zhang, PhD, Antonio Cavazos, Helen Ma, MS, Carol A. Bivins, RN, Allison Wade, Shadiat L Adewale, Susan Tse, Robin Thomas, Kenneth Vaughan, RN, Sherry A. Pierce, BSN, BA, Jing Ning, PhD, Wei Qiao, PhD, John S. Welch, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 645.

https://doi.org/10.1182/blood-2019-128547

Published: 2019

Journal Articles

A Specific Mesenchymal Stem and Progenitor Cell (MSPC) Subpopulation with a Multi-Potent Gene Signature Is Transcriptionally Altered in the Setting of Myelodysplastic Syndrome (MDS) in Primary Human Bone Marrow Aspirates

Thomas J Fountaine, MD, Mark W LaMere, BA, Daniel K Byun, BS, Jason R Myers, MS, John M Ashton, PhD, Jane L. Liesveld, MD, Youmna Kfoury, PhD, David T. Scadden, MD, Michael W. Becker, MD, Laura M. Calvi, MD

Blood (2019) 134 (Supplement_1): 1708.

https://doi.org/10.1182/blood-2019-130227

Published: 2019

Journal Articles

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Ian Ferguson, BA, Yu-Hsiu T. Lin, BA, Sami Tuomivaara, PhD, Jeffrey L. Wolf, MD, Thomas G. Martin, III, MD, Sandy W. Wong, MD, Nina D. Shah, MD, Christoph Driessen, MD, Brian G. Van Ness, PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1803.

https://doi.org/10.1182/blood-2019-131681

Published: 2019

Journal Articles

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

Blood (2019) 134 (Supplement_1): 1711.

https://doi.org/10.1182/blood-2019-124978

Published: 2019

Journal Articles

Comprehensive Analysis of MYC Translocations in Multiple Myeloma By Whole Genome Sequencing and Whole Transcriptome Sequencing

Sonja Seliger, Verena Geirhos, Torsten Haferlach, MD, Wolfgang Kern, MD, Wencke Walter, PhD, Manja Meggendorfer, PhD, Constance Baer, PhD, Anna Stengel, PhD, Claudia Haferlach, MD

Blood (2019) 134 (Supplement_1): 1774.

https://doi.org/10.1182/blood-2019-124704

Published: 2019

Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD

Blood (2019) 134 (Supplement_1): 1867.

https://doi.org/10.1182/blood-2019-125629

Published: 2019

Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD

Blood (2019) 134 (Supplement_1): 1907.

https://doi.org/10.1182/blood-2019-123652

Published: 2019

Journal Articles

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

Brian J Ball, Meier Hsu, MS, Sean M. Devlin, PhD, Christopher Famulare, MS, Sheng F Cai, MDPhD, Andrew Dunbar, MD, Zachary D. Epstein-Peterson, MD, Kamal Menghrajani, MD, Jacob L Glass, MDPhD, Justin Taylor, MD, Aaron D Viny, MDMS, Aaron D Goldberg, MDPhD, Martin S. Tallman, MD, Eytan M. Stein, MD

Blood (2019) 134 (Supplement_1): 18.

https://doi.org/10.1182/blood-2019-125319

Published: 2019

Journal Articles

Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL Patients

Chaitra S. Ujjani, MD, Lindsey E. Roeker, MD, Mazyar Shadman, MD MPH, Kate J Whitaker, BA, Allison P. Jacob, Mark B. Geyer, MD, Colleen Dorsey, BSN, RN, Andrew D. Zelenetz, MD PhD, Anthony R. Mato, MDMSCE

Blood (2019) 134 (Supplement_1): 1758.

https://doi.org/10.1182/blood-2019-124002

Published: 2019

Journal Articles

TEM-MM-101: A Phase I/IIa Dose Escalation Study Evaluating the Safety and Activity of Autologous CD34+ Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-α2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy

Bernhard Gentner, MD, Francesca Farina, MD, Matteo Giovanni Carrabba, MD, Magda Marcatti, MD, Stefania Girlanda, MD, Gabriele Antonarelli, MD, Capotondo Alessia, PhD, Stefania Mazzoleni, PhD, Carlo Russo, MD, Luigi Naldini, MD PhD, Fabio Ciceri, MD

Blood (2019) 134 (Supplement_1): 2064.

https://doi.org/10.1182/blood-2019-123749

Published: 2019

Journal Articles

Analysis of the Genetic Background in Patients with Myeloid Malignancies and Divergent Findings Regarding Blasts As Determined By Cytomorphology and Flow Cytometry

Wolfgang Kern, MD, Manja Meggendorfer, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 2095.

https://doi.org/10.1182/blood-2019-130157

Published: 2019

NARROW

Vacuolization of hematopoietic precursors: an enigma with multiple etiologies

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Bone marrow aspirate LE cells at acute lupus presentation

Acid-Based Decalcification Methods Compromise Genomic Profiling from DNA and RNA

Single Cell Transcriptomic Analysis of the Multiple Myeloma Bone Marrow Identifies a Unique Inflammatory Stromal Cell Population Associated with TNF Signaling

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

A Specific Mesenchymal Stem and Progenitor Cell (MSPC) Subpopulation with a Multi-Potent Gene Signature Is Transcriptionally Altered in the Setting of Myelodysplastic Syndrome (MDS) in Primary Human Bone Marrow Aspirates

Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology

Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes

Comprehensive Analysis of MYC Translocations in Multiple Myeloma By Whole Genome Sequencing and Whole Transcriptome Sequencing

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy

Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL Patients

TEM-MM-101: A Phase I/IIa Dose Escalation Study Evaluating the Safety and Activity of Autologous CD34+ Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-α2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy

Analysis of the Genetic Background in Patients with Myeloid Malignancies and Divergent Findings Regarding Blasts As Determined By Cytomorphology and Flow Cytometry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only